학술대회 안내 사전등록 안내 초록등록 안내 초록등록/관리 숙박및교통 안내


мȸ ǥ ʷ

ǥ : ȣ - 500784   177 
The Role of Dobutamine Stress Echocardiography For Screening Modality Of Cirrhotic Cardiomyopathy In Patients With Liver Cirrhosis
연세대학교 원주의과대학 순환기내과¹ 소화기내과²
최현민¹, 김장영¹ 백순구² 이경훈¹ 안민수¹ 유병수¹ 이승환¹ 윤정한¹ 최경훈¹
Background: Cirrhotic cardiomyopathy(C-CMP) defined as blunted systolic and diastolic contractile responses to stress are more common in advanced liver cirrhosis (LC). It can aggravate complications of LC and also increase cardiovascular morbidity and mortality after liver transplantation. But screening methods for C-CMP are absent. This study was designed to define chronotrophic and inotropic response assessed by low (20μg/kg/min) and high-dose (40μg/kg/min) dobutamine stress echocardiography (DSE) in patients with advanced LC. Method: We enrolled consecutive 28 advanced LC (mean age; 49.4±8.3 yrs) with Child-Pugh score > 5 and seven normal controls (mean age; 47.0±10.8 yrs) underwent DSE. We measured ejection fraction (EF), LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) by modified Simpson’s method. Diastolic parameters (E/A ratio, and deceleration time) were also measured in baseline and high-dose. Blunted inotrop! ic and chronotrophic response defined to increment of EF and heart rate by less than 5% during dobutamine stress. Results: Demographic and echocardiographic findings were described as table. There was no adverse event during DSE. Conclusions: Our results showed 24.1 %( n=7) of patients with advanced liver cirrhosis showed blunted inotropic and chronotrophic response with diastolic dysfunction. Our results suggested DSE might be a useful and safe modality for screening of C-CMP.

Control

(n=8)

LC with normal response (n=21)

LC with blunted response (n=7)

p-value

Age (years)

47.0±10.8

49.9±8.8

47.7±6.5

0.682

Total bilirubin (mg/dL)

NA

2.5±1.9

3.5±1.6

0.236

Child-Pugh score

NA

7.1±1.2

6.3±1.9

0.502

Pulse rate (/min)

Baseline

High-dose

?

67.4±16.7

99.1±17.4

?

74.6±9.1

116.5±15.0

?

64.7±11.3

61.7±16.2

?

0.102

0.000

EF (%)

Baseline

High-dose

?

67.7±6.7

81.5±6.1

?

71.1±8.0

84.7±5.7

?

67.6±5.6

63.1±5.6

?

0.347

0.000

LVEDV (ml)

Baseline

High-dose

81.9±20.4

85.2±30.8

90.5±28.4

85.2±30.8

97.1±15.5

100.0±12.0

?

0.502

0.407

LVESV (ml)

Baseline

High-dose

?

27.2±9.4

15.6±7.6

?

26.5±12.5

13.5±8.1

?

30.2±4.9

36.7±6.2

?

0.743

0.000

E/A ratio

Baseline

High-dose

?

0.9±0.2

0.8±0.2

?

1.0±0.3

0.8±0.3

?

1.2±0.4

1.4±0.5

?

0.254

0.002

DT(msec)

Baseline

High-dose

?

212.7±33.1

217.4±64.8

?

207.4±35.4

168.2±42.3

?

206.7±25.5

141.4±67.1

?

0.918

0.025



[ư]